Myriad's myChoice To Be Used In More Cancer Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
Myriad is continuing its mission to expand its companion diagnostics reach by teaming up with Tesaro and Merck to evaluate their breast and ovarian cancer drugs, and expanding its partnership with Abbvie into lung cancer. .
You may also be interested in...
August M&A Analysis: Slow Month Highlighted By Unique Technologies
The dog-days of summer produced just a handful of mergers and acquisitions in the medtech sector and no blockbuster deals. However, several companies made smaller deals for innovative products in a range of sectors including IVDs, cardiovascular devices, and ophthalmology.
Myriad To Enter Neuroscience Market With $225m Assurex Acquisition
In its bid to develop more targeted diagnostics and build future partnerships with pharma companies, Myriad has signed a $225m deal, plus milestones, to acquire Assurex Health.
More Companion Diagnostic Deals For Qiagen And Myriad
Qiagen’s agreement Tokai Pharmaceuticals targets circulating tumor cells, and Myriad Genetics has extended its partnership with BioMarin Pharmaceutical focused on Myriad's myChoice HRD companion diagnostic.